Myriad Genetics, Inc. (MYGN) — Analyst outlook / Analyst consensus target is. Based on 36 analyst ratings, the consensus is bullish — 8 Buy, 22 Hold, 6 Sell.
The consensus price target is $6.00, representing an upside of 22.2% from the current price $4.91.
Analysts estimate Earnings Per Share (EPS) of $0.13 and revenue of $0.84B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.41 vs est $0.13 (missed -1167.9%). 2025: actual $-3.96 vs est $0.01 (missed -40661.3%). Analyst accuracy: 0%.
MYGN Stock — 12-Month Price Forecast
$6.00
▲ +22.20% Upside
Average Price Target
Based on 36 Wall Street analysts offering 12-month price targets for Myriad Genetics, Inc., the price target is $6.00.
The average price target represents a +22.20% change from the last price of $4.91.
MYGN Analyst Ratings
Hold
Based on 36 analysts giving stock ratings to Myriad Genetics, Inc. in the past 3 months
EPS Estimates — MYGN
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.41
vs Est $0.13
▼ 109.4% off
2025
Actual –$3.96
vs Est $0.01
▼ 100.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect the company to turn profitable.
Revenue Estimates — MYGN
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.838B
vs Est $0.839B
▼ 0.2% off
2025
Actual $0.825B
vs Est $0.822B
▲ 0.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
